Age at start of maintenance (years), median (range) |
7 (1–17) |
5
(2–17) |
0.3 |
Weight (kg), median (range) |
26.9 (10.2–128) |
20.9 (11–88.7) |
0.2 |
BSA (m2), median (range) |
0.99 (0.48–2.55) |
0.81
(0.51–1.98) |
0.2 |
Sex, number (%) |
Sex, number (%) |
Sex, number (%) |
0.29 |
Female
|
18 (56)
|
28 (44)
|
|
Male
|
14 (44)
|
35 (56)
|
|
Race, number (%) |
Race, number (%) |
Race, number (%) |
|
White
|
18 (56)
|
38 (60)
|
0.52
|
Black
|
7 (22)
|
8 (13)
|
|
Other
|
7 (22)
|
15 (24)
|
|
Asian
|
0 (0)
|
2 (3)
|
|
Ethnicity, number (%) |
Ethnicity, number (%) |
Ethnicity, number (%) |
0.62 |
Non-Hispanic/Latino
|
25 (78)
|
45 (71)
|
|
Hispanic/Latino
|
7 (22)
|
18 (29)
|
|
Trisomy 21 (DS), number (%) |
1 (3) |
4 (6) |
0.58 |
TPMT genotype, number (%) |
TPMT genotype, number (%) |
TPMT genotype, number (%) |
0.13 |
*1/*1
|
20 (63)
|
43 (68)
|
|
*1/*3A or *1/*3C
|
2 (6)
|
10 (16)
|
|
Not genotyped
|
10 (31)
|
10 (16)
|
|
NUDT15 genotype, number (%) |
NUDT15 genotype, number
(%) |
NUDT15 genotype, number (%) |
0.7 |
*1/*1
|
16 (50)
|
28 (44)
|
|
*1/*4
|
0 (0)
|
1 (2)
|
|
Not genotyped
|
16 (50)
|
34 (54)
|
|
TPMT phenotype, number (%) |
TPMT phenotype, number (%) |
TPMT phenotype, number (%) |
0.12 |
Low
|
1 (3)
|
1 (2)
|
|
Intermediate
|
1 (3)
|
12 (19)
|
|
High (normal)
|
28 (88)
|
49 (77)
|
|
Not collected
|
2 (6)
|
1 (2)
|
|
NUDT15 phenotype, number (%) |
NUDT15 phenotype, number
(%) |
NUDT15 phenotype, number (%) |
0.7 |
Normal
|
16 (50)
|
29 (46)
|
|
Intermediate
|
0 (0)
|
1 (2)
|
|
Not collected
|
16 (50)
|
33 (52)
|
|
Diagnosis, number (%) |
Diagnosis, number (%) |
Diagnosis, number (%) |
0.73 |
T-Cell ALL
|
28 (88)
|
57 (90)
|
|
B-Cell ALL
|
4 (12)
|
6 (10)
|
|
Risk status, number (%) |
Risk status, number (%) |
Risk status,
number (%) |
0.65 |
Standard
|
16 (50)
|
31 (49)
|
|
Intermediate
|
3 (9)
|
3 (5)
|
|
High
|
13 (41)
|
29 (46)
|
|
6MP dosage form, number (%) |
6MP dosage form, number (%) |
6MP dosage
form, number (%) |
0.82 |
Tablet
|
21 (66)
|
43 (68)
|
|
Oral Solution
|
11 (34)
|
20 (32)
|
|
Starting daily dose of 6MP (mg/m2/day), median (range) |
75 (71–77) |
75 (38–78) |
0.58 |
Abbreviations: 6MP, 6-mercaptopurine; ALL, acute lymphoblastic leukemia;
BSA, body surface area; DS, Down syndrome; NUDT15, nudix
hydrolase 15 gene; TPMT, thiopurine methyltransferase gene. |
Abbreviations: 6MP, 6-mercaptopurine; ALL, acute lymphoblastic leukemia;
BSA, body surface area; DS, Down syndrome; NUDT15, nudix
hydrolase 15 gene; TPMT, thiopurine methyltransferase gene. |
Abbreviations: 6MP, 6-mercaptopurine; ALL, acute lymphoblastic leukemia;
BSA, body surface area; DS, Down syndrome; NUDT15, nudix
hydrolase 15 gene; TPMT, thiopurine methyltransferase gene. |
Abbreviations: 6MP, 6-mercaptopurine; ALL, acute lymphoblastic leukemia;
BSA, body surface area; DS, Down syndrome; NUDT15, nudix
hydrolase 15 gene; TPMT, thiopurine methyltransferase
gene. |